The principles of agonist pharmacotherapy for psychostimulant dependence

Drug and Alcohol Review

Volumn 27, Issue 3, 2008, Pages 301-308

  Shearer, James ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Pharmacotherapy; Psychostimulant drugs; Review

Indexed keywords

BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; MODAFINIL;

ADDICTION; ARTICLE; HEROIN DEPENDENCE; HUMAN; RANDOMIZED CONTROLLED TRIAL; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE AGONISTS; HEROIN DEPENDENCE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TOBACCO USE DISORDER;

EID: 41549143904     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1080/09595230801927372     Document Type: Article

References (113)

1. White F, Kalivas P. Neuroadaptions involved in amphetamine and cocaine addiction. Drug Alcohol Depend 1998;51:141-53.
2. Rawson R, Huber A, Brethen P, et al. Methamphetamine and cocaine users: differences in characteristics and treatment retention. J Psychoact Drugs 2000;21:233-8.
3. Copeland A, Sorenson J. Differences between methamphetamine users and cocaine users in treatment. Drug Alcohol Depend 2001;62:91-5.
4. Wise R. Neurobiology of addiction. Curr Opin Neurobiol 1996;6:243-51.
5. Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991;14:299-302.
6. Koob G. Neurobiology of addiction: toward the development of new therapies. Ann NY Acad Sci 2000,909:170 - 85.
7. Volkow N, Fowler J, Wang G-J, Swanson J. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004;9:557-69.
8. Bardo M. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol 1998;12:37-67.
9. Gold M, Miller M. Cocaine (and crack): neurobiology. In: Lowinson J, Ruiz P, Millman R, Langrod J, eds. Substance abuse: a comprehensive textbook, chapter 15. Baltimore: Williams & Wilkins, 1997:166-81.
10. Dackis C, Gold M. New concepts in cocaine addiction: the dopamine depletion theory. Neurosci Biobehav Rev 1985;9:469-77.
11. Dackis C, O'Brien C. Cocaine dependence: a disease of the brain's reward centers. J Subst Abuse Treat 2001;12:111-17.
12. Spanagel R, Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 1999;22:521-7.
13. Kuhar M, Pilotte N. Neurochemical changes in cocaine withdrawal. Trends Pharmacol Sci 1996;17:260-4.
14. Nader MA, Morgan D, Gage HD, et al. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci 2006;9:1050-6.
15. Volkow ND, Wang GJ, Fowler JS, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997;386:830-3.
16. Volkow ND, Chang L, Wang G-J, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001;158:377-82.
17. Ross E. Pharmacodynamics. In: Goodman L, Gilman A, eds. Goodman & Gilman's The pharmacological basis of therapeutics, chapter 2, 9th edn. New York: McGraw-Hill, 1996:29-41.
18. Neal M. Medical pharmacology at a glance, 4th edn. Oxford: Blackwell Science, 2002.
19. Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med 1969;280:1372-5.
20. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotics addicts in Hong Kong. Lancet 1979;2:485-8.
21. Gunne L-M, Grönbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend 1981;7:249-56.
22. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000;283:1303-10.
23. Gearing FR, Schweitzer MD. An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. Am J Epidemiol 1974;100:101-12.
24. Caplehorn JRM, Dalton MSYM, Cluff MC, Petrenas AM. Retention in methadone maintenance and heroin addicts' risk of death. Addiction 1994;89:203-7.
25. Langendam MW, van Brussel GHA, Coutinho RA, van Ameijden EJC. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health 2001;91:774-80.
26. Julien R. A primer of drug action. New York: Henry Holt and Company, 2001.
27. Mattick R, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo versus methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004;3:CD002207.
28. Kirchmayer U, Davoli M, Verster A, Amato L, Ferri M, Perucci CA. A systematic review on the efficacy of naltrexone maintenance treatment in opioid treatment. Addiction 2002;97:1241 -9.
29. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2002;4:CD000146.
30. Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation, European Respiratory Society. EurRespir J 1999 1999;13:238-46.
31. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an {alpha} 4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55.
32. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an {alpha} 4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63.
33. Soares B, Lima M, Reisser A, Farrell M. Dopamine agonists for cocaine dependence [Cochrane Review]. The Cochrane Library, Issue 4, 2006. Chichester: John Wiley & Sons, Ltd, 2006.
34. Sevarino K, Oliveto A, Kosten T. Neurobiological adaptions to psychostimulants and opiates as a basis of treatment development. Ann NY Acad Sci 2000;909:51-87.
35. Malcolm R, Moore J, Kajdasz D, Cochrane C. Adverse events occurring in the treatment of cocaine dependence. Am J Addict 1997;6:117-23.
36. Dackis C, O'Brien C. Cocaine dependence: the challenge for pharmacotherapy. Curr Opin Psychiatry 2002;15: 261-7.
37. Kampman K, Volpicelli J, Alterman A, Cornish J, O'Brien C. Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms. Am J Psychiatry 2000;157:2052-4.
38. Kampman K, Dackis C, Lynch K, et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend 2006;85:129-37.
39. Shearer J, Gowing L. Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug Alcohol Rev 2004;23:203-11.
40. Nann-Vernotica E, Donny E, Bigelow G, Walsh S. Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacologia 2001;155:38-47.
41. Haney M, Ward A, Foltin R, Fischman M. Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacologia 2001;155:330-7.
42. McCance-Katz E, Kosten T, Kosten T. Going from the bedside back to the bench with ecopipam: a new strategy for cocaine pharmacotherapy development. Psychopharmacology 2001;155:327-9.
43. Evans S, Walsh S, Levin F, Foltin R, Fischman M, Bigelow G. Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans. Drug Alcohol Depend 2001;64:271 - 83.
44. Grabowski J, Rhoades H, Silverman P. Risperidone for the treatment of cocaine dependence: randomized, doubleblind trial. J Clin Psychopharmacol 2000;20:305 - 10.
45. Kampman K, Pettinati H, Lynch K, Sparkman T, O'Brien C. A pilot study of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend 2003;70:265-73.
46. Fleming P. Prescribing amphetamine to amphetamine users as a harm reduction measure. Int J Drug Policy 1998;9:339-44.
47. Shearer J, Sherman J, Wodak A, van Beek I. Substitution therapy for amphetamine users. Drug Alcohol Rev 2002;21:179-85.
48. Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004;29:969-81.
49. Lile J. Pharamcological determinants of the reinforcing effects of psychostimulants: relation to agonist substitution treatment. Exp Clin Psychopharmacol 2006;14:20-33.
50. Volkow ND, Wang GJ, Fowler JS. Imaging studies of cocaine in the human brain and studies of the cocaine addict. Ann NY Acad Sci 1997;820:1325-31.
51. Shearer J. Psychosocial approaches to psychostimulant dependence: a systematic review. J Subst Abuse Treat 2007;32:41-52.
52. Baker A, Lee N. A review of psychosocial interventions for amphetamine use. Drug Alcohol Rev 2003;22:323-35.
53. Shearer J, Wodak A, Mattick R, et al. Pilot randomised controlled study of dexamphetamine for amphetamine dependence. Addiction 2001;96:1289-96.
54. Shearer J, Wodak A, van Beek I, Mattick R, Lewis J. Pilot randomised double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003;98:1137-41.
55. Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double blind randomised clinical trial. J Clin Psychopharmacol 2001;21:522-6.
56. McBride A, Sullivan G, Blewett A, Morgan S. Amphetamine prescribing as a harm reduction measure: a preliminary study. Addict Res 1997;5:95-112.
57. Charnaud B, Griffiths V. Levels of intravenous drug misuse among clients prescribed oral dexamphetamine or oral methadone: a comparison. Drug Alcohol Depend 1998;52:79-84.
58. Klee H, Wright S, Carnwath T, Merrill J. The role of substitute therapy in the treatment of problem amphetamine use. Drug Alcohol Rev 2001;20:417-29.
59. Merrill J, McBride A, Pates R, et al. Dexamphetamine substitution as a treatment of amphetamine dependence: a two-centre randomised controlled trial. Final report submitted to the Department of Health. London: UK Department of Health, 2004.
60. Grabowski J, Roache J, Schmitz J, Rhoades H, Creson D, Korzun A. Replacement medication for cocaine dependence. Exp Clin Psychopharmacol 1997;17:247-9.
61. Schubiner H, Saules K, Arfken C, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002;10:286-94.
62. Tiihonen J, Kuoppasalmi K, Foehr J, et al. A comparison of aripiprazole, methylphenidate and placebo for amphetamine dependence. Am J Psychiatry 2007;164:160 - 2.
63. Fleming P, Roberts D. Is the prescription of amphetamine justified as a harm reduction measure? J Roy Soc Health 1994;114:127-31.
64. Sherman J. Dexamphetamine for 'speed' addiction. Med J Aust 1990;153:306.
65. White R. Dexamphetamine substitution in the treatment of amphetamine abuse: an initial investigation. Addiction 2000;95:229-38.
66. Carnwath T, Garvey T, Holland M. The prescription of dexamphetamine to patients with schizophrenia and amphetamine dependence. J Psychopharmacol 2002;16:373-7.
67. White R, Thompson M, Windsor D, Walsh M, Cox D, Chamaud B. Dexamphetamine substitute prescribing in pregnancy: a 10-year retrospective audit. J Subst Use 2006;11:205-16.
68. Spear J, Alderton D. Psychosis associated with prescribed dexamphetamine use [letter]. Aust NZ J Psychiatry 2003;37:383.
69. Hawks D, Mitcheson M, Ogborne A, Edwards G. Abuse of methylamphetamine. BMJ 1969;85:715-21.
70. Kall K. Amphetamine abuse in Sweden. In: Klee H, ed. Amphetamine misuse. Amsterdam: Harwood Academic Publishers, 1997:215-33.
71. Merrill J, McBride A, Pates R. Messages and findings from the Department of Health drugs misuse research initiative: final overview report. Drugs Educ Prev Policy 2005;12:94-7.
72. White J, Wickes W, Longo M. Randomised controlled trial of d-amphetamine maintenance for treatment of methamphetamine dependence. Paper presented at the Australasian Professional Society in Alcohol and Other Drugs (APSAD), 2006, Cairns, Queensland.
73. Gawin F, Riordan C, Kleber H. Methylphenidate treatment of cocaine abusers without attention deficit disorder: a negative report. Am J Drug Alcohol Abuse 1985;11:193-7.
74. Khantzian E, Gawin F, Riordan C, Kleber H. Methylphenidate treatment of cocaine dependence: a preliminary report. J Subst Abuse Treat 1984;1:107-12.
75. Levin F, Evans S, McDowell D, Kleber H. Methylphenidate treatment for cocaine abusers with attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998;59:300-5.
76. Somoza E, Winhusen T, Bridge T, et al. An open-label pilot study of methylphendaite in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder. J Act Dis 2004;23:77-92.
77. Margolin A, Kosten TR, Avants SK, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 1995;40: 125-31.
78. Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006;63:219-28.
79. Newton T, Roache J, de la Garza R, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006;31:1537-44.
80. Mooney M, Schmitz J, Moeller F, Grabowski J. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend 2007;88:214-23.
81. Cousins M, Roberts D, de Wit H. GABAb receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend 2002;65:209-20.
82. Kalivas P. Glutamate systems in cocaine addiction. Curr Opin Pharmacol 2004;4:23-29.
83. Lacey M. Neurotransmitter receptors and ionic conductances regulating the activity of neurones in substantia nigra pars compacta and ventral tegmental area. Prog Brain Res 1993;99:251-76.
84. Wood P. Actions of the GABAergic agents on dopamine metabolism in the nigrostriatal pathway of the rat. J Pharmacol Exp Ther 1982;222:674-9.
85. Pycock C, Horton R. Evidence for an accumbens-pallidal pathway in the rat and its possible gabaminergic control. Brain Res 1976;110:629-34.
86. Tzschentke T, Schmidt W. Glutamatergic mechanisms in addiction. Mol Psychiatry 2003;8:373-82.
87. Kalivas P, McFarland K, Bowers S, Szumlinski K, Xi Z, Baker D. Glutamate transmission and addiction to cocaine. Ann NY Acad Sci 2003;1003:169-75.
88. Cornish J, Kalivas P. Cocaine sensitization and craving: differing roles for dopamine and glutamate in the nucleus accumbens. J Act Dis 2001;20:43-54.
89. Baker D, McFarland K, Lake R, et al. Neuroadaptions in cystine - glutamate exchange underlie cocaine relapse. Nat Neurosci 2003;6:743-9.
90. Dackis C. New treatments for cocaine abuse. Drug Discov Today Ther Strategies 2005;2:79-86.
91. Keys A, Mark G, Emre N, Meshul C. Reduced glutamate immunolabeling in the nucleus accumbens following extended withdrawal from self-administered cocaine. Synapse 1998;30:393 - 401.
92. Murillo-Rodriguez E, Haro R, Palomero-Rivero M, Millan-Aldaco D, Drucker-Colin R. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res 2007;176:353-7.
93. Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006;319:561-9.
94. Willie J, Renthal W, Chemelli R, et al. Modafinil more effectively induces wakefulness in norexin-null mice than wild-type littermates. Neuroscience 2005;130:983-95.
95. Scammell T, Estabrooke I, McCarthy M, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J. Neurosci 2000;20:8620-8.
96. Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance - a review of abuse liability issues. Ann Clin Psychiatry 2004;16:101-9.
97. Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, Barbanoj M. Differential effects of a new central adrenergic agonist- modafinil and d-amphetamine on sleep and early morning behaviour in young healthy volunteers. Int J Clin Pharmacol Res 1989;9:183-5.
98. Robertson P, Hellriegel E. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003;42:123-37.
99. Ballas C, Kim D, Baldassano C, Hoeh N. Modafinil: past, present and future. Exp Opin Neurother 2002;2:449-57.
100. de la Mora M, Aguilar-Garcia A, Ramon-Frias T, et al. Effects of the vigilance promoting drug modafinil on the synthesis of GABA and glutamate on slices of rat hypothalamus. Neurosci Lett 1999;259:181-5.
101. Ferraro L, Antonelli T, Tanganelli S, et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial proptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999;20:346 - 56.
102. Ferraro L, Antonelli T, O'Connor W, Tanganelli S, Rambert F, Fuxe K. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 1996;82883 - 7.
103. Tanganelli S, Perez de la Mora M, Ferraro L, Mendez-Franco J, Beani L, Rambert F. Modafinil and cortical gamma-aminobutyric acid outflow: modulation by 5-HT neurotoxins. Eur J Pharmacol 1995;273:63-71.
104. Dackis C, Lynch K, Yu E, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003;70:29-37.
105. Stoops W, Lile J, Fillmore M, Glaser P, Rush C. Reinforcing effects of modafinil: influence of dose and behavioural demands following drug administration. Psychopharmacology 2005;182:186-93.
106. Turner D, Robbins T, Clark L, Aron A, Dowson J, Sahakian B. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 2003;165:260-9.
107. Jasinski D, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 2000;23:149-56.
108. Jasinski D. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000;14:53-60.
109. Malcolm R, Brook S, Moak D, DeVane L, Czepowicz V. Clinical applications of modafinil in stimulant abusers: low abuse potential. Am J Addict 2002;11:247-9.
110. Comacho A, Stein M. Modafinil for social phobia and amphetamine dependence [letter]. Am J Psychiatry 2002;159:1947-8.
111. McGregor C, White J, Srisurapanont M, Mitchell A, Wickes W. Investigation of potential pharmacotherapies for acute amphetamine withdrawal: open-label pilot studies of mirtazapine and modafinil. Paper presented at the Australian Professional Society on Alcohol and Other Drugs (APSAD), 2004, Fremantle, Australia.
112. Malcolm R, Swayngim K, Donovan J, et al. Modafinil and cocaine interactions. Am J Drug Alcohol Abuse 2006;32:577-87.
113. Dackis C, Kampman K, Lynch K, Pettinati H, O'Brien C. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30:205-11.